THERE iS considerable evidence that the progressive growth of solid tumours is dependent on their ability to induce the growth of new blood vessels from their host, (Folkman, 1978; Gullino, 1978) .
Accepted 11 Jtune 1979 Original work by Folkman et al. (1971) indicated that such neovascularization was induced by a humoral mediator secreted by the tumour, which they called tumour angiogenesis factor (TAF). They reported -1r IG. I. tA)1;llRc' eiorioauianitoic membrane, (UArNI) slowing a strong neovascular response to purified TAF. The bloo(d vessels can be seen to proliferate in a "spoke-whlieel" pattern con-erging tox%vards the souirce of TAFI'. (B) A control CAMI treated with lactose alone. For (Schor et al., unpub.) .
Crude TAF (mol. wt , 105) resulting from gel filtration on Sephadex G100 of the treated tissue homogenate was freezedried and served as starting material for the subsequent purification. The first step was the separation of protein components by chromatography on DEAE cellulose using a convex salt gradient between 0 and 0-3m NaCl. At the end of the gradient the column was further washed with 0-5M NaCl. Activity could generally be detected in one or two of the eluted peaks, but the eluting positions of active material varied in different batches of TAF. Fig. 2 gives the position of the active peaks in 5 batches of TAF tested. All fractions from the DEAE column were applied individually to an affinity-chromatography column prepared by coupling absorbed TAF anti- concentrated and reapplied to a DEAE cellulose column. The peak emerged in a position identical to its previous one. This suggests that the charge contribution of TAF to the overall charge of the protein carrier is not significant. On dialysis in ammonium acetate (pH 3.7) the bound material from an affinitychromatography column equilibrated within 30 min and the material outside the bag was highly active. Since this suggested that the active component was of low molecular weight we applied the bound fraction from an affinity column to a Biogel P2 column (excluLsion limit 2500 mol. wt) with 10% isopropanol in water as packing and eluting solvent. An active peak emerged from the included portion (Fig.  3) (Fig. 4) . (This figure must be an approximation since in this system we do not find a straight-line relationship between all marker molecules of known mol. wt below 500, although the amount of variation from linearity is not great). The active peak was followed by 2 much larger but lower mol.-wt peaks which were inactive. The rapid equilibration of the material between the retentate and dialysate and the position of its elution on Biogel P2 indicate a very low mol. wt. The chemical nature of the small molecule, which we believe to be the true tumour angiogenic factor, is currently being investigated. It is not a prostaglandin, a protein or a peptide and neither is it a nucleic acid. We are also interested in the carrier molecules involved, as these may be either artifacts of preparation or natural binding carriers which are needed for transport of the molecule in vivo.
It may be of interest that neither our purified TAF nor an angiogenic factor which we have detected in synovium from an actively inflamed ankylosing spondylitic joint (results to be published) gives a precipitin line against TAF antibody. This may be due to the small size of the angiogenic factor(s). Human kidney tumours, which are the only human tumours we have so far investigated, do share com mon antigenic determinants with rat TAF (Phillips & Kumar, 1979) . It is likely that angiogenic factor or factors are not unique to tumour cells, but that there is an excess production of them in the malignant cell. We feel that once the chemical nature of the angiogenic factor is established, it mav have both prophylactic and diagnostic implications in huiman mnalignant disease, or in other conditions wvhere angiogenesis is a feature.
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